glp 1 weight loss indication GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists GLP-1-based therapies for diabetes, obesity

No significant associations were observed for anorexia nervosa, broad depression, major depressive disorder, or suicide and intentional self-harm

These injections can either be administered by a medical professional or be self-administered and will start on a very low dosage, slowly increasing in amount each month before reaching the target dose to ensure no severe reaction to the medication occurs

Novo Nordisk's patent for Saxenda expires later this year, and rivals Teva, Pfizer and Mylan are all expected to launch generic versions of liraglutide later in 2024

Emerging GLP-1 options and future coverage possibilities The GLP-1 landscape is evolving rapidly, and emerging alternatives may offer new insurance coverage opportunities

Among anti-obesity medication (AOM) users, the switch rate is just 2 percent, while type 2 diabetes (T2D) patients show a slightly higher rate at 7 percent, likely due to broader payer coverage for branded diabetes therapies